(NU/1257) Clinical Trial Unit or Contracted Research Organisation to set up and manage Vision DMD Phase 2b and extension study
What the buyer wrote
This is an EU Open Tender. The scope of this contract relates specifically to the Phase 2b Randomized, Double-blind, Parallel Placebo- and Active-controlled Study to Assess the Efficacy and Safety of Vamorolone in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) and the extension study that will follow this. A registered Clinical Trial Unit (CTU) or Contracted Research Organisation (CRO) is required to set up and manage the clinical trial at sites in [UK/Australia/Israel/Sweden]. The CTU / CRO will be carrying out delegated duties on behalf of the sponsor, ReveraGen, but will be receiving payments for these duties from the Vision-DMD Horizon 2020 grant, coordinated by Newcastle Unive…
Details
- What the buyer calls it
- (NU/1257) Clinical Trial Unit or Contracted Research Organisation to set up and manage Vision DMD Phase 2b and extension study
- How they are buying
- Advertised, open to anyoneAny supplier could bid without being invited first.
- Type
- services
- Work starts
- 16 Apr 2017
- Work ends
- 30 Nov 2020
- Kind of work
- Research, evaluation and insight
Who the buyer named
Dave Anderson was the named contact on this notice.